AB-205

N/A

Report date: 2024/01/26 20:05:29

Base Information

Drug NameAB-205

Drug Alias NameAB-205 + HDT-ASCTAB-205 + mdUCBTEngineered human umbilical vein endothelial cells(Angiocrine Bioscience)Universal E-CEL® Cell TherapyAB-205 +[7]

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Umbilical vein endothelial cell therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsLymphoma, Non-HodgkinHodgkin Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAngiocrine Bioscience Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAngiocrine Bioscience Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, Non-HodgkinHodgkin Disease

Other Information

ATC CodeN/A